Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026)
Structure Therapeutics' (GPCR) quarterly Other Non-Current Liabilities came in at $863000.0 in Q1 2026, up 180.19% year-on-year from $308000.0 in Q1 2025, and up 33.38% quarter-over-quarter from $647000.0 in Q4 2025.
Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Structure Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $863000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 180.19% year-over-year to $863000.0 in Q1 2026; TTM through Mar 2026 was $863000.0, a 180.19% increase from a year earlier, with the FY2025 full-year figure at $647000.0, up 114.24% from the prior year.
- Other Non-Current Liabilities rose to $863000.0 in Q1 2026 per GPCR's latest filing, from $647000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $863000.0 in Q1 2026 and bottomed at $281000.0 in Q3 2023.
- The 4-year median for Other Non-Current Liabilities is $308500.0 (2024), against an average of $394600.0.
- Across the five-year window, Other Non-Current Liabilities climbed 1.34% in 2024 and soared 180.19% in 2026, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $298000.0 in 2023, then advanced by 1.34% to $302000.0 in 2024, then jumped by 114.24% to $647000.0 in 2025, then soared by 33.38% to $863000.0 in 2026.
- Per Business Quant, the three latest GPCR Other Non-Current Liabilities figures stand at $863000.0 (Q1 2026), $647000.0 (Q4 2025), and $325000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Structure Therapeutics | 11.04 Bn | 11.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 863,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Sep 30, 2025 | 325,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 309,000.00 |
| Mar 31, 2024 | 296,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 281,000.00 |